ENMD-2076: Interim Phase II data

Data from 16 patients with locally advanced or metastatic fibrolamellar carcinoma in stage 1 of a 2-stage, open-label, U.S. Phase II trial showed that once-daily 250 mg oral ENMD-2076 met the stage 1 ...